Robert Orlowski, Deputy Chair of Lymphoma/Myeloma, Vice Chair of MM Research, and Florence Maude Thomas Cancer Research Professor at the University of Texas MD Anderson Cancer Center, shared a post on X:
“Myeloma Paper of the Day:
Long-term follow-up of HOVON 143 trial in older NDMM patients finds higher early- and non-relapse related mortality in ultra-frail patients and patients who were frail due to impairments vs patients who were frail (by IMWG-FI) based on age alone.”
Title: Frail subgroups determine heterogeneous outcomes in older patients with NDMM – long-term follow-up of the HOVON 143 trial
Authors: Febe Smits, Kaz Groen, Mark-David Levin, Claudia A.M. Stege, Roel J.W. van Kampen, Ellen van der Spek, Inger S. Nijhof, Yavuz M. Bilgin, Noortje Thielen, Inge Ludwig, Esther G.M. de Waal, Yorick Sandberg, Alain Kentos, Gert-Jan Timmers, Josien C. Regelink, Matthijs Westerman, Koen de Heer, Marie-Christiane MB Vekemans, Nazik Durdu-Rayman, Nicole C.H.P. de Graauw, Maarten R. Seefat, Niels W.C.J. van de Donk, Paula F Ypma, Kazem Nasserinejad, Sonja Zweegman
You can read the Full Article on Blood Advances.
You can find more posts featuring Robert Orlowski on OncoDaily.
